These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22038939)

  • 21. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats.
    Yokoyama O; Yusup A; Miwa Y; Oyama N; Aoki Y; Akino H
    J Urol; 2005 Nov; 174(5):2032-6. PubMed ID: 16217388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results.
    Boy S; Schurch B; Mehnert U; Mehring G; Karsenty G; Reitz A
    BJU Int; 2007 Sep; 100(3):574-8. PubMed ID: 17669142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
    Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
    Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication.
    Pontari MA; Mohamed FB; Lebovitch S; Moonat S; Lebed B; Ruggieri MR; Faro SH
    J Urol; 2010 May; 183(5):1899-905. PubMed ID: 20303095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
    Kaplan SA; Schneider T; Foote JE; Guan Z; Carlsson M; Gong J
    BJU Int; 2011 May; 107(9):1432-40. PubMed ID: 20860717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
    Herschorn S; Kaplan SA; Sun F; Ntanios F
    Urology; 2014 May; 83(5):1023-9. PubMed ID: 24582119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Serati M; Salvatore S; Uccella S; Cardozo L; Bolis P
    Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.